Biomatrix (BXM) Looking Great Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Donald Gravenor who wrote (108)	10/11/1997 2:52:00 AM
From: Philip H. Lee	of 569

Re: Taxol market trends. Do you have any information regarding Taxol's expected annual sales growth? Are limited supplies restraining Taxol's revenue growth? The only sales info I found were that 1996 worldwide sales were $813 million, and $444 million through 1997 Q2. Source: ww2.newswire.ca >I prescribe a lot of taxol. Here, in Canada, Bristol Meyers Squibb is pricing taxol (paclitaxel) very agressively, and just cut its' price by about 1/3. I expect that it will be cut further, to keep their market share.<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next